Michael Trauner
Overview
Explore the profile of Michael Trauner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
686
Citations
20750
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Manns M, Bergquist A, Karlsen T, Levy C, Muir A, Ponsioen C, et al.
Nat Rev Dis Primers
. 2025 Mar;
11(1):17.
PMID: 40082445
Primary sclerosing cholangitis (PSC) is a chronic biliary inflammation associated with periductular fibrosis of the intrahepatic and extrahepatic bile ducts leading to strictures, bacterial cholangitis, decompensated liver disease and need...
2.
3.
Nash P, Kerschbaumer A, Konzett V, Aletaha D, Dorner T, Fleischmann R, et al.
Ann Rheum Dis
. 2025 Mar;
PMID: 40037995
In light of the introduction of new Janus kinase inhibitors (JAKi), new indications for JAKi and recent safety considerations that have arisen since the preceding consensus statement on JAKi therapy,...
4.
Zhu C, Boucheron N, Al-Rubaye O, Chung B, Thorbjornsen L, Kocher T, et al.
Gut
. 2025 Mar;
PMID: 40032499
Background: 24-Nor-ursodeoxycholic acid (NorUDCA) is a novel therapeutic bile acid for treating immune-mediated cholestatic liver diseases, such as primary sclerosing cholangitis (PSC). Objective: Since PSC strongly associates with T helper-type-like...
5.
Laschtowitz A, Lindberg E, Liebhoff A, Liebig L, Casar C, Steinmann S, et al.
JHEP Rep
. 2025 Feb;
7(3):101267.
PMID: 39996122
Background & Aims: Primary sclerosing cholangitis (PSC) is a chronic heterogenous cholangiopathy with unknown etiology where chronic inflammation of the bile ducts leads to multifocal biliary strictures and biliary fibrosis...
6.
Konzett V, Smolen J, Nash P, Aletaha D, Winthrop K, Dorner T, et al.
Ann Rheum Dis
. 2025 Feb;
PMID: 39934019
Objective: This systematic literature review (SLR) on efficacy outcomes was performed to inform the 2024 update of the expert consensus statement on the treatment of immune-mediated inflammatory diseases (IMIDs) with...
7.
Konzett V, Smolen J, Nash P, Winthrop K, Aletaha D, Dorner T, et al.
Ann Rheum Dis
. 2025 Feb;
PMID: 39934016
Objectives: This systematic literature review (SLR) on safety outcomes was performed to inform the 2024 update of the expert consensus statement on the treatment of immune-mediated inflammatory diseases (IMIDs) with...
8.
Balcar L, Dominik N, Mozayani B, Semmler G, Halilbasic E, Mandorfer M, et al.
Liver Int
. 2025 Jan;
45(2):e16175.
PMID: 39807082
Background And Aims: Porto-sinusoidal vascular disorder (PSVD) is a rare vascular liver disorder characterised by specific histological findings in the absence of cirrhosis, which is poorly understood in terms of...
9.
Hofer B, Simbrunner B, Konigshofer P, Brusilovskaya K, Petrenko O, Taru V, et al.
United European Gastroenterol J
. 2024 Dec;
PMID: 39708052
Background: Portal hypertension (PH) resulting from static and dynamic intrahepatic changes drives liver-related complications even after removing the underlying aetiological factor. Objective: We investigated the impact of inflammation on the...
10.
Poetter-Lang S, Bastati N, Attenberger U, Halilbasic E, Trauner M, Ba-Ssalamah A
Eur Radiol
. 2024 Dec;
34(12):7647-7649.
PMID: 39688723
No abstract available.